Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits
Go back to Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits| METABASIS THERAPEUT (NASDAQ: MBRX) | Delayed: 3.12 +0.24 (8.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.88 | 52 Week High | $9.58 | |||
| Open | $3.01 | 52 Week Low | $2.34 | |||
| Day High | $3.16 | P/E | N/A | |||
| Day Low | $2.94 | EPS | $-0.34 | |||
| Volume | 437,313 | |||||
